Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 23
Phase 41

Trial Status

Completed3
Recruiting1
Other1

Role Distribution

Principal Investigator2
Other Roles3
PI Rate40%

Activity Timeline

Clinical Trials (5)

NCT07203196Not ApplicableActive Not Recruiting
Circadian Health Regulation and Optimization for Rejuvenation Outcomes
Aging, HealthyBlood Sugar (Glucose) ControlBlood Sugar; High+2 more
PrincipalinvestigatorStart date: 2025-10-22
NCT06865885Phase 4Recruiting
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
Cardiometabolic SyndromeDrug InteractionsLDL-Cholersterol Lowering+1 more
PrincipalinvestigatorStart date: 2025-04-02
NCT06305793Phase 2Completed
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
Long Coronavirus Disease 2019 (Covid19)Long COVIDLong Covid-19
StudychairStart date: 2024-05-08
NCT06305780Phase 2Completed
RECOVER-AUTONOMIC Platform Protocol
Long COVIDLong Covid-19
StudychairStart date: 2024-03-11
NCT06305806Phase 2Completed
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
Long COVIDLong Covid-19
StudychairStart date: 2024-03-11

Research Network

Collaboration Network

16 collaborators·24 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Satchidananda Panda, PhD

Salk Institute for Biological Studies

Similar
1 trials

Shared therapeutic areas:

Healthy AgingBlood Sugar (Glucose) ControlBlood Sugar; High+2 more

Worked with same sponsors:

Salk Institute for Biological StudiesUniversity of California, San Diego
Collaborated on 1 trial
Similarity Score54%

Eric D Adler, MD

University of California, San Diego

Moderately Similar
2 trials

Shared therapeutic areas:

Cardiometabolic SyndromeDrug InteractionsLDL-Cholersterol Lowering+1 more

Worked with same sponsors:

NovartisUniversity of California, San Diego
Collaborated on 1 trial
Similarity Score44%

Michael Wilkinson, MD

University of California, San Diego

Moderately Similar
1 trials

Shared therapeutic areas:

Cardiometabolic SyndromeDrug InteractionsLDL-Cholersterol Lowering+1 more

Worked with same sponsors:

NovartisUniversity of California, San Diego
Collaborated on 1 trial
Similarity Score44%

Antoinette Birs, MD

University of California, San Diego

Moderately Similar
1 trials

Shared therapeutic areas:

Cardiometabolic SyndromeDrug InteractionsLDL-Cholersterol Lowering+1 more

Worked with same sponsors:

NovartisUniversity of California, San Diego
Collaborated on 1 trial
Similarity Score44%

Cyndya Shibao, MD

Vanderbilt University Medical Center

Moderately Similar
5 trials

Shared therapeutic areas:

Post-Acute COVID-19 SyndromeLong Covid-19Long Coronavirus Disease 2019 (Covid19)

Worked with same sponsors:

Kanecia Obie Zimmerman
Collaborated on 3 trials
Similarity Score42%

Peter Novak, MD

Harvard

Moderately Similar
3 trials

Shared therapeutic areas:

Post-Acute COVID-19 SyndromeLong Covid-19Long Coronavirus Disease 2019 (Covid19)

Worked with same sponsors:

Kanecia Obie Zimmerman
Collaborated on 3 trials
Similarity Score42%

Tae Chung, MD

Johns Hopkins University

Moderately Similar
3 trials

Shared therapeutic areas:

Post-Acute COVID-19 SyndromeLong Covid-19Long Coronavirus Disease 2019 (Covid19)

Worked with same sponsors:

Kanecia Obie Zimmerman
Collaborated on 3 trials
Similarity Score42%

Christopher Grainger, MD

Duke Clinical Research Institute

Moderately Similar
2 trials

Shared therapeutic areas:

Post-Acute COVID-19 SyndromeLong Covid-19Long Coronavirus Disease 2019 (Covid19)

Worked with same sponsors:

Kanecia Obie Zimmerman
Collaborated on 2 trials
Similarity Score38%

David Putrino, PT, PhD

Icahn School of Medicine at Mount Sinai

Related
8 trials

Shared therapeutic areas:

Long Covid-19Post-Acute COVID-19 Syndrome
Similarity Score5%

Leora Horwitz, MD

NYU Langone Health

Related
7 trials

Shared therapeutic areas:

Post-Acute COVID-19 SyndromeLong Covid-19
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT07203196Not ApplicablePrincipalInvestigator

Circadian Health Regulation and Optimization for Rejuvenation Outcomes

Aging, HealthyBlood Sugar (Glucose) ControlBlood Sugar; High+2 more
Active Not Recruiting
NCT06865885Phase 4PrincipalInvestigator

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

Cardiometabolic SyndromeDrug InteractionsLDL-Cholersterol Lowering+1 more
Recruiting
NCT06305793Phase 2StudyChair

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Long Coronavirus Disease 2019 (Covid19)Long COVIDLong Covid-19
Completed
NCT06305780Phase 2StudyChair

RECOVER-AUTONOMIC Platform Protocol

Long COVIDLong Covid-19
Completed
NCT06305806Phase 2StudyChair

RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)

Long COVIDLong Covid-19
Completed

All 5 trials loaded